FDA proposes warning, not outright ban, for ephedra

Levetiracetam and clobazam can cause Drug Reaction with Eosinophilia and Systemic Symptoms, which can start as a rash but progress quickly, potentially resulting in injury to internal organs, hospitalization, and death.

Drug Topics recently sat down with Steve Hoffart, PharmD, owner and PIC at Magnolia Pharmacy north of Houston, to discuss the importance of pharmacists getting involved in advocacy.

Prior research has shown the association between various socioeconomic variables and lower adherence to diabetic retinopathy screening, but few have elaborated on the patient perspective to understand the reason behind this association.

Todd Eury of the Pharmacy Podcast Network is joined by Josh Bolin of the NABP to talk about DSCSA, what benefits it will provide, and how to make sure your pharmacy is ready when it goes into effect this November.

The treatment from Arcutis Biotherapeutics has a Prescription Drug User Fee Act (PDUFA) target action date of July 7, 2024.

This season marks the fourth to be classified as high severity since the 2009 influenza A(H1N1) pandemic.